miRNA Assays NanoString Platform Qiagen Platform WaferGen Platform
A/A B/A C/A D/A A/A B/A C/A D/A A/A B/A C/A D/A
HSA-let-7d 1 0.85 3.02 2.29 1.00 1.37 5.06 5.58 1.00 1.02 2.48 2.59
HSA-let-7g 1 0.99 7.18 5.78 1.00 0.78 9.34 10.75 1.00 1.13 4.11 4.49
HSA-let-7i 1 1.03 4.27 2.97 1.00 0.86 4.78 5.03 1.00 1.03 3.20 3.17
HSA-MIR-100 1 1.05 2.89 2.57 1.00 0.85 4.30 3.61 1.00 0.96 2.74 3.17
HSA-MIR-10a 1 1.13 8.61 6.29 1.00 1.18 58.49 50.91 1.00 0.97 3.99 4.51
HSA-MIR-126 1 0.92 4.08 3.56 1.00 0.86 4.68 3.63 1.00 0.98 4.30 4.68
HSA-MIR-140 1 1.13 1.96 2.63 1.00 0.94 7.38 7.82 1.00 1.18 5.85 6.59
HSA-MIR-151 1 1.41 4.85 5.61 1.00 0.80 4.20 2.48 1.00 0.93 3.58 3.40
HSA-MIR-15a 1 0.88 7.62 6.43 1.00 0.82 7.31 9.74 1.00 0.92 8.01 7.74
HSA-MIR-15b 1 0.87 2.61 2.46 1.00 1.17 2.84 4.02 1.00 1.07 2.47 2.78
HSA-MIR-16 1 1.05 3.78 4.02 1.00 0.87 3.54 2.58 1.00 0.98 3.76 4.03
HSA-MIR-191 1 1.23 3.31 2.40 1.00 0.92 4.50 3.54 1.00 1.08 3.07 3.14
HSA-MIR-200c 1 1.10 0.01 0.01 1.00 0.62 0.00 0.00 1.00 1.00 0.00 0.00
HSA-MIR-205 1 0.82 0.00 0.00 1.00 0.77 0.00 0.00 1.00 0.97 0.00 0.00
HSA-MIR-29a 1 1.12 3.80 3.54 1.00 0.79 4.23 4.26 1.00 1.02 2.89 3.63
HSA-MIR-29b 1 1.09 2.28 5.12 1.00 0.93 3.93 9.65 1.00 0.79 9.07 9.39
HSA-MIR-29c 1 0.84 2.70 2.87 1.00 0.83 4.17 4.33 1.00 0.81 2.92 3.57
HSA-MIR-30a 1 0.64 4.71 5.11 1.00 0.66 4.30 4.91 1.00 0.76 5.04 5.12
HSA-MIR-30b 1 1.05 3.83 4.48 1.00 0.64 4.54 3.51 1.00 0.99 4.91 5.33
HSA-MIR-31 1 1.10 0.09 0.09 1.00 0.47 0.03 0.03 1.00 0.90 0.02 0.02
HSA-MIR-361 1 0.94 2.09 2.29 1.00 0.82 4.96 5.36 1.00 0.90 4.36 5.49
HSA-MIR-363 1 0.81 0.29 0.23 1.00 0.83 0.15 0.12 1.00 0.92 0.01 0.01
HSA-MIR-720 1 1.71 2.12 2.85 1.00 0.92 1.61 5.02 1.00 1.09 0.45 0.98
HSA-MIR-9 1 0.98 0.06 0.06 1.00 0.66 0.03 0.02 1.00 1.08 0.01 0.00
HSA-MIR-98 1 1.11 2.60 2.63 1.00 0.93 2.17 2.86 1.00 1.08 2.31 2.28
HSA-MIR-99a 1 1.18 0.55 0.40 1.00 0.80 0.29 0.25 1.00 1.02 2.32 2.77
Fold-change Data for miRNAs Common to all Three Platforms
Table 2: Comparison of the fold-change data for the 26 miRNA assays common to all three platforms. For each platform, miRNA levels are expressed relative to the control sample A. Two-fold or greater increases in miRNA levels relative to sample A are in bold; two-fold or greater decreases in miRNA levels compared to sample A are in italics.
Goto home»